Otsuka ties up with Denmark's Lundbeck on psychiatric drugs

Otsuka ties up with Denmark's Lundbeck on psychiatric drugs

TOKYO, Japan - Otsuka Pharmaceutical Co. President Taro Iwamoto and Danish drugmaker H. Lundbeck A/S CEO Ulf Wiinberg shake hands in Tokyo on Nov. 11, 2011. The two companies agreed to share costs to develop and market drugs to treat central neurological diseases including schizophrenia.

  • Product Code
  • ILEA001164273
  • Registered date
  • 2011/11/11 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2011 Kyodo News
  • Media size
  • 1414 × 1303 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 363.38(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    JAL taps Tottori as 1st female president

    JAL taps Tottori as 1st female president

    Japan Airlines Co. President Yuji Akasaka (L) and senior managing executive officer Mitsuko Tottori, a former flight attendant, shake hands at a press conference in Tokyo on Jan. 17, 2024. Tottori was named to become the company's first female president in April.
      Press conference by Japan's SBI, Taiwan's PSMC

      Press conference by Japan's SBI, Taiwan's PSMC

      Yoshitaka Kitao (L), chairman and president of Japanese financial group SBI Holdings Inc., and Frank Huang, chairman of Taiwan's Powerchip Semiconductor Manufacturing Corp., attend a press conference in Tokyo on Oct. 31, 2023. The two companies said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
        Press conference by Japan's SBI, Taiwan's PSMC

        Press conference by Japan's SBI, Taiwan's PSMC

        Yoshitaka Kitao (L), chairman and president of Japanese financial group SBI Holdings Inc., and Frank Huang, chairman of Taiwan's Powerchip Semiconductor Manufacturing Corp., shake hands at a press conference in Tokyo on Oct. 31, 2023. The two companies said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
          Toyota, Idemitsu to tie up in next-generation batteries

          Toyota, Idemitsu to tie up in next-generation batteries

          Toyota Motor Corp. President Koji Sato (L) and Shunichi Kito, president of energy company Idemitsu Kosan Co., shake hands at a press conference in Tokyo on Oct. 12, 2023, after the two companies announced they will tie up to develop technology for the mass production of next-generation all-solid-state batteries.
            New loyalty point program

            New loyalty point program

            Sumitomo Mitsui Financial Group Inc. President Jun Ota (L) and Culture Convenience Club Co. CEO Muneaki Masuda pose for a photo in front of the logo of their new loyalty point program during a press conference in Tokyo on June 13, 2023. The two companies said earlier that CCC's T-Point program and Sumitomo Mitsui's V Point program will be merged into one, with the integrated program to be launched under the new V-Point program possibly in the spring of 2024.
              New loyalty point program

              New loyalty point program

              Sumitomo Mitsui Financial Group Inc. President Jun Ota (L) and Culture Convenience Club Co. CEO Muneaki Masuda shake hands in front of the logo of their new loyalty point program during a press conference in Tokyo on June 13, 2023. The two companies said earlier that CCC's T-Point program and Sumitomo Mitsui's V Point program will be merged into one, with the integrated program to be launched under the new V-Point program possibly in the spring of 2024.
                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      Honda's group net profit down for 1st time in 3 yrs

                      Honda's group net profit down for 1st time in 3 yrs

                      TOKYO, April 28 Kyodo - Tetsuo Iwamura, executive vice president of Honda Motor Co., announces the company's earnings results for the year ended in March 2015 at a press conference in Tokyo on April 28, 2015. Honda's group net profit fell for the first time in three years, down 8.9 percent from a year earlier to 522.76 billion yen ($4.4 billion), hurt by recall-related costs and sluggish sales in Japan.